GAMMA Investing LLC Grows Stock Holdings in Merck & Co., Inc. $MRK

GAMMA Investing LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 6.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 94,992 shares of the company’s stock after purchasing an additional 5,736 shares during the quarter. GAMMA Investing LLC’s holdings in Merck & Co., Inc. were worth $12,207,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. during the fourth quarter worth approximately $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC increased its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. Adjusted loss per share of $0.13 was also better than the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth engine, while the newer injectable version of the cancer treatment exceeded Wall Street expectations by more than $200 million. Strength in oncology and other newer products helped support the improved sales outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its full-year 2026 revenue forecast to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus. Management also highlighted regulatory, clinical and pipeline milestones that could support longer-term growth. MRK Q2 Earnings and Sales Beat Estimates, 2026 Sales View Raised
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate, because of charges associated with the acquisition of Terns Pharmaceuticals. The resulting earnings pressure offsets part of the benefit from the stronger sales outlook. Merck hikes revenue outlook but cuts profit guidance due to deal charges

Analyst Upgrades and Downgrades

MRK has been the topic of several recent research reports. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Barclays lifted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $134.50.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $128.28 on Wednesday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $135.05. The stock’s fifty day moving average is $123.45 and its two-hundred day moving average is $118.78. The company has a market capitalization of $316.83 billion, a P/E ratio of 36.14, a P/E/G ratio of 5.07 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts expect that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.